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Abstract
Pituitary adenomas constitute the most frequent neuroendocrine pathology in humans. Current
therapies include surgery, radiotherapy and pharmacological approaches. Although useful, none of
them offers a permanent cure. Current research efforts to implement gene therapy in pituitary tumors
include the treatment of experimental adenomas with adenoviral vector-mediated transfer of the
suicide gene for thymidine kinase, which converts the prodrug ganciclovir into a toxic metabolite.
In some cases, the suicide transgene has been placed under the control of pituitary cell-type specific
promoters. Also, regulatable adenoviral vector systems are being assessed in gene therapy approaches
for experimental pituitary tumors. Although the efficiency and safety of current viral vectors must
be optimized before clinical use, they remain as highly promising therapeutic tools.
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INTRODUCTION
Pituitary adenomas constitute the most frequent neuroendocrine pathology in humans,
comprising up to 15% of primary intracranial tumors [1]. Also, pituitary tumors represent the
most prevalent pathology in old female rats [2]. Clinical manifestations of pituitary adenomas
arise from overproduction of hormones in microadenomas or from mass effects in larger
tumors.
There are six types of hormone-producing pituitary adenomas which reflect the cell type that
originated the tumor (Table 1). These tumor types are prolactin (PRL)- and growth hormone
(GH)-secreting tumors that cause reproductive abnormalities [3] and the syndromes of
acromegaly [4], respectively; corticotropin (ACTH)-producing tumors that cause Cushing’s
disease [4] gonadotropin- and thyrotropin-secreting tumors that cause abnormalities in their
respective axes and null-cell type adenomas that produce none of the above hormones [5,6].
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Mass effects of enlarging tumors usually include visual field defects resulting from
compression of the optic nerves, headaches, hypopituitarism and, rarely, invasion into the skull
base causing multiple intracranial nerve palsies. Only exceptionally are pituitary tumors truly
malignant with distant metastases [7].
Current therapies for pituitary tumors include surgery and radiotherapy, as well as
pharmacological approaches for some types [6,8]. Transsphenoidal surgery has proven to be
highly effective for microadenomas but not for macroadenomas [9]. In both cases post-surgical
complications, like the appearance of a new pituitary dysfunction, diabetes insipidus and
sometimes fistula formation, develop even in patients operated on by specialist surgeons
[10]. Pharmacological therapies, with dopamine agonists like bromocriptine, cabergoline and
quinagolide, have met with remarkable success in shrinking prolactinomas and reducing the
hyperprolactinemia associated with them [11]. Unfortunately, a significant rate of side effects
like nausea, vomiting, postural hypotension, dizziness, headaches, and constipation is present
in long-term treatments with these drugs [12]. In patients with GH-producing adenomas,
somatostatin analogues and depot preparations of octreotide can lower the usual
hypersomatotropinemia to levels compatible with acceptable long-term survival [13].
Treatment with octreotide of 27 newly diagnosed acromegalic patients for 6 months, followed
by treatment with a long-acting octreotide preparation for additional 6 months, resulted in 79%
of the patients having mean serum GH levels below 5 mU/liter, 53% having normal IGF-I
levels, and 73% of the patients showing greater than 30% tumor shrinkage [14]. None of the
aforementioned pharmacological treatments cure the tumors which will usually recur if the
medications are discontinued. Radiotherapy is usually used as an adjunctive treatment after
pituitary tumor surgery. Although long-term irradiation is often effective to prevent tumor
regrowth, it usually causes complications, the most frequent (58 to 83%) of which is
hypopituitarism [15]. Other less frequent complications associated with conventional
radiotherapy for pituitary adenomas are 2% optic chiasmal injury and 0.2% radiation brain
necrosis. Although rare, radiation-induced fibrosarcomas and osteosarcomas have been
reported [16]. Focused radiotherapy, either in the form of stereotactic multiarc radiotherapy or
gamma-knife that can be applied to a small area, have the advantage to reduce damage to normal
pituitary tissue and surrounding vascular and neuronal structures [7,17].
In summary, although important advances have been made in the treatment of pituitary tumors,
a fully satisfactory therapy is not yet available. In this context, gene therapy appears as a
potentially useful alternative for the treatment of pituitary tumors. Although research efforts
to apply this methodology to the hypophysis are relatively recent, promising experimental
results, discussed later in this review, have already emerged.
VIRAL VECTOR-BASED GENE DELIVERY METHODS
Although current gene delivery methods comprise viral and non-viral approaches, use of the
latter for gene therapy of pituitary tumors has, to our knowledge, not been documented.
Therefore, they will not be discussed. The wide use of recombinant viral vectors as gene
delivery systems is due to their high efficiency for gene transfer (Table 2). In the pituitary
gland, gene therapy strategies have mainly relied, up to now, on the use of adenovirus-derived
vectors, although herpes-derived vectors have also been employed in some studies.
Adenoviral vectors
Adenovirus(Ad)-derived vectors have been used for both basic and therapeutic applications in
the neuroendocrine system. Ads are non-enveloped DNA viruses, with a genome of 36 Kb,
which possess the ability to infect a wide variety of dividing and non-dividing cells.
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The cellular receptors for Ad are the high affinity receptor called CAR (Coxackie and
Adenovirus Receptor), which attaches to the viral fiber knob protein [18] and the avb3/5
integrins which interact with the viral penton base [19]. After endocytosis, the virus escapes
from the endosomal compartment to the cytosol and docks onto the nuclear pore complex,
where the viral DNA plus some associated proteins are translocated into the nucleus. There,
the viral genome remains in a non-integrated (episomal) state. Adenoviral genes have been
classified as early genes (which encode regulatory proteins that are expressed before DNA
replication) and late genes (expressed after DNA replication and encoding structural proteins).
The early E1 gene product is the main trans-activator of adenoviral gene transcription,
including those genes needed for viral replication. This genomic region is deleted in adenoviral
vectors in order to render them replication-defective and to prevent expression of the viral
genome. This E1 genomic region must be complemented in trans (i.e., in a separate DNA) to
replicate the vector, which is often done by means of a cell line, like the HEK 293, stably
transfected with the deleted viral genes [20]. In some viral vectors other adenoviral genes have
been deleted in order both to make more space for cloning exogenous genes and to diminish
the immunogenicity and cytotoxicity of the vector. First generation recombinant adenoviral
vectors usually lacked E1 and E3 genomic regions, the latter being deleted to make more space
for exogenous sequences. However, despite the E1 deletion, some activation of viral gene
transcription still occurs, perhaps mediated by cellular proteins with E1-like activity. Viral
protein expression elicits a strong immune response, characterized by cytotoxic T lymphocytes
(CTL), which eliminates the infected cells [21]. To overcome this limitation,, other genomic
regions have been deleted in newer adenoviral vectors. The most promising of these are the so
called ‘gutless’ or ‘helper dependent’ adenovectors, HD-Ads, (up to 35 kb of foreign DNA),
in which all adenoviral genes are deleted and have only the ends of the adenoviral genome
(inverted terminal repeats or ITR, which are necessary for viral DNA replication) and the
encapsidation signal. As the vector cannot express any viral protein, generation of gutless
vectors requires that all Ad genes be provided in trans, usually by coinfection with an
adenovirus, called ‘helper virus’ [22]. Since the helper virus used to generate the gutless vector
remains as a contaminant, several systems have been designed to minimize helper titres in
gutless viral stocks [23]. With these multiple-deleted vectors, the risk of chance generation of
replication-competent viruses is decreased, since several recombination events are required to
regenerate a replication-competent Ad.
Adenoviral vectors have several advantages over other vectors (Table 2). 1) As indicated above,
Ads can efficiently infect cells in replicative state as well as cells out of the cell cycle; 2) they
have a capacity of up to 35 Kb of DNA (in HD-Ads), which in many instances provides enough
space for transgene(s) and regulatory sequences; 3) the biology of these viruses is well known,
and there is a wide range of adenoviral systems available; 4) Ads are easy to manipulate; 5)
the fact that the Ad genome does not integrate into the host genome avoids the risk of insertional
mutagenesis. [20].
As mentioned above, the critical limitation of adenoviral vectors comes from the usually strong
host’s immune response against the viral particle and the infected cells. This immune response
limits the long-term expression of transgenes because CTL kill the infected cells and prevent
re-administration of the vector. Current strategies to overcome Ad-induced immune responses
include the use of Ad vectors carrying immuno-suppressant genes [24; also see below],
administration of immunosuppressant drugs like cyclosporin [25] and oral tolerization to viral
antigens [26].
Herpes Simplex Virus type 1 (HSV1)-derived vectors
Another type of vectors that has been used for gene transfer in the pituitary gland corresponds
to those derived from the HSV-1. This is a double stranded DNA virus with an envelope derived
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from the host cell. The virus has 38 genes that are non-essential for the viral cycle and could
therefore be deleted thus generating recombinant vectors with sufficient space to clone more
than one transgene or regulatory sequences like specific or regulated promoters. HSV-1 can
establish two types of infections: a lytic cycle or, in some neurons, a latency state. The lytic
cycle is characterized by a cytopathic effect, in part due to the effect of infected cell proteins
(ICP), coded for by immediate early (IE) genes. One of these ICP, ICP4, is the main factor
implicated in the transition from the immediate early phase to the early phase of the lytic cycle.
In the latent state, there is a very low level of viral gene transcription, which results in low
levels of latency associated viral RNAs [27].
There are two types of HSV-1-derived vectors: amplicons, which will not be discussed here,
and recombinant viruses. In the latter, the transgene(s) is cloned into the HSV-1 genome [for
a review see 28]. There are two major types of these, called the first- and second-generation
HSV-1-derived vectors. The first-generation vectors have a mutation or deletion in a single
essential immediate early (IE) gene. A relevant example of these vectors is the tsK, which is
the only type of herpes-derived vector so far used in the pituitary gñand (see below). This vector
is a temperature-sensitive (ts) mutant of the HSV-1, which has a point mutation in the IE3 gene
that hinders the replication process at 37 °C but not at 31°C. The IE3 gene was chosen because
its protein product, ICP4, is the major trans-activator of early genes, and consequently, the
expression of viral early and late genes is reduced when IE3 is inactive. The transgenes are
cloned into the thymidine kinase (TK) locus under the control of an active HSV-1 IE promoter.
Wild type revertants arise with a relatively high frequency during vector preparation and
contaminate viral stocks with replication-competent viruses. A negative feature of first-
generation herpes-derived vectors is their cytotoxicity, which stems from the fact that they still
express toxic viral genes [29]. The second-generation HSV recombinant vectors have deletions
in more than one gene, which makes them less cytotoxic. So far, they have not been used in
the pituitary gland.
Other Viral Vector Systems
Retroviruses and lentiviruses are RNA viruses which are considered advantageous because
they are integrating viruses. The ability to incorporate their DNA into the host allows for the
therapeutic gene to be permanently present in the genome of the cells infected and can be passed
on to future generations of that cell. Lentiviruses have an additional advantage due to their
ability to transduce dividing and nondividing cells [30,31]. This unique characteristic makes
them strong candidates for gene therapy. Unfortunately there are disadvantages that go along
with these integrating vectors. The possibility of insertional mutagenesis is a significant
concern or integration within an oncogene which could therefore lead to cancer [32,33]. With
lentiviruses, the fear that recombination could lead to HIV infection in gene therapy patients
is a drawback, even though the vectors have been constructed in such a way that recombining
is a negligible possibility.
EXPERIMENTAL GENE THERAPY IN PITUITARY TUMORS
Reporter gene transfer studies
Initial studies with adenoviral and herpes-derived vectors demonstrated that these two vector
systems could be used to efficiently transfer different types of genes into normal rat anterior
pituitary (AP) cells in primary culture as well as in the corticotropic AtT20 and
somatomammotropic GH3 tumor cell lines [34,35]. Interestingly, neoplastic AP cells were
found to be more susceptible to viral vector-mediated transduction than were normal AP cells.
Include also the paper by Windeat et al, Endocrinology, it was the first report of transcriptional
targeting and expression in the AP both in vitro and in vivo using the PRL promoter to drive
transgene expression encoded within Ad vectors.
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Direct stereotaxic injection into the sheep pituitary of Ad vectors carrying the E. coli β-
galactosidase (∃-gal) gene under the control of either the human PRL (hPRL) or hCMV
promoters led to high levels of transgene expression up to 7 days after surgery. Histologic
examination of these pituitaries revealed varying degrees of inflammatory response, with
periglandular fibrosis, lymphocytic infiltrate and venulitis in almost all cases [36].
Other in vivo studies in rats have shown that intravascular administration of adenoviral vectors,
harboring the ∃-gal gene under the control of the hGH or the glycoprotein hormone ∀-subunit
promoters, fail to express the transgene at pituitary level. On the contrary, stereotaxic injection
of these vectors into the pituitary of rats succeeded in selectively expressing the transgene in
the appropriate AP cell populations [37].
The HSV1-derived vector tsK was shown to be highly effective for in vivo transfer of the ∃-
gal gene in rat pituitary prolactinomas [38,39].
Human pituitary gonadotroph and somatotroph adenoma cells were transduced in vitro using
a human immunodeficiency virus (HIV)-type 1-derived vector encoding the enhanced green
fluorescent protein (eGFP) gene under the phosphoglycerate kinase promoter [40].
Suicide gene therapy
Suicide gene therapy has been the more widely used approach to implement gene therapy for
pituitary tumors, both in vitro and in vivo.
A recombinant adenoviral (RAd) vector, RAdTK, harboring the HSV-1 thymidine kinase (TK)
suicide gene under the control of the human cytomegalovirus (hCMV) promoter, was used to
transfer the TK gene to GH3 and AtT20 cells. Incubation of RAdTK-treated GH3 and AtT20
cells with the prodrug ganciclovir (which after phosphorylation by viral TK becomes toxic)
caused ample destruction of the cultures [41]. In the same study, estrogen/sulpiride-induced
rat prolactinomas were stereotaxically injected with the same RAdTK. Subsequent injection
of the host animals with two daily i.p. doses of 25 mg ganciclovir/kg for 7 days succeeded in
partially reducing AP tumor size and serum PRL levels. Gene therapy, using adenoviral vectors
harboring the TK gene under the control of specific AP hormone promoters, namely the human
GH and glycoprotein hormone ∀-subunit promoters, was effective for the treatment of GH3
and ∀-subunit producing pituitary tumor cell lines in vitro, respectively [42]. An adenoviral
vector, encoding the TK gene under the control of the hPRL promoter was also effective to
induce apoptosis in GH3 cell cultures exposed to ganciclovir. It did not significantly reduce
the growth and PRL-secretory rate of estrogen-induced rat prolactinomas in vivo [43].
Adenoviral vectors, harboring the TK gene under both a promiscuous hCMV and the hPRL
promoter, showed expression of the transgene for up to 3 months in situ in the normal rat
anterior pituitary [44], while nude mice carrying GH3 cell-grafted subcutaneous tumors were
effectively treated with an adenoviral vector harboring the TK gene under the control of the
hGH promoter [42].
A hybrid cDNA encoding a chimeric protein corresponding to HSV1-TK fused to enhanced
GFP which still emits green fluorescense and retains TK suicide activity [45] was cloned into
an adenoviral vector, termed RAd-(GFP/TK)fus, which successfully transduced experimental
rat pituitary adenomas in vivo [46; Fig. 1]. This vector was also shown to express high
fluorescence levels in cultures of the lung tumor cell line A549 and kill these cells when
gancyclovir was added to the cultures (Fig. 2).
A GH cell-type specific adenoviral vector was constructed in which a stuffer DNA fragment,
flanked by two loxP sequences, was placed between the hGH promoter and the diphtheria toxin
gene (GHp-loxP-DT). When the GH-producing cell line GH4 was co-transduced with this
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vector and with another one harboring the expression cassette for GHp-Cre, rapid destruction
of the cultures occurred. Furthermore, subcutaneous GH4 tumors, generated in nude mice,
involuted rapidly when topically injected with the above vectors in the tumor area [47].
Incubation of GH3 cells with RAd’s expressing the gene for either tumor necrosis factor-α
(TNFα)- or FasL, two pro-apoptotic molecules whose receptors are present on the membrane
of lactotropic cells, was shown to increase apoptotic activity in these cells [48]. This study
suggests that pro-apoptotic gene therapy may constitute a suitable alternative to TK gene
therapy for the treatment of certain types of pituitary tumors, like prolactinamas.
The retinoblastoma mutant mouse
Another type of gene therapy strategy for the treatment of pituitary cancer is that based on the
transfer of a gene(s) with the ability to rescue the normal phenotype of tumor cells. This
approach has been implemented in mice heterozygous for the retinoblastoma (RB) tumor
suppressor gene (Rb+/− mice). Such mice develop and succumb to characteristic pituitary
intermediate lobe melanotroph tumors [49]. Transduction of tumor melanotrophic cells with a
recombinant adenoviral vector (rAd5.R.Rb) carrying the human RB cDNA under the control
of its own promoter, showed a high level of efficiency both in vitro and in vivo [50].
Furthermore, intracranial delivery of this vector to mice carrying actively growing
melanotrophic tumors significantly reduced tumor growth and prolonged animal survival.
Melanotrophic tumor proliferative index and apoptotic rates were markedly lowered in the
rAd5.R.Rb-treated animals, which also showed growth-inhibitory dopaminergic neuron
reinnervation of melanotrophic cells. [50].
Insulin-like growth factor I gene therapy
The pituitary gland produces several growth factors [51,52] that may affect the function and
proliferation of pituitary cells through autocrine or paracrine action [53]. One such factor,
insulin-like growth factor type I (IGF-I), which is abundant and homogeneously distributed
throughout the anterior and intermediate pituitary lobes [54] has shown promise for the
treatment of experimental pituitary adenomas. In effect, IGF-I gene therapy was recently
reported to induce a partial regression of estrogen-induced prolactinomas in rats [46]. In this
type of tumors, IGF-I gene therapy was also reported to normalize the somatotropic cell
population and reduce GH secretion which is also elevated in these adenomas [55].
REGULATABLE VECTOR SYSTEMS FOR THE TREATMENT OF PITUITARY
TUMORS
Two central objectives in the development of viral vectors are the achievement of cell-type
specificity for transgene delivery, and the design of vectors where, once the transgene is
incorporated into the target cell, its expression can be regulated by small molecules. Cell-type
specificity has already been achieved in pituitary tumor cells by placing transgenes under the
control of cell-type specific promoters like the GH, ∀-glycoprotein and PRL promoters for
pituitary tumor cells, as noted previously.
Early inducible gene expression systems encountered limitations such as pleiotropic effects of
the inducer, basal leakiness, toxicity of inducing agents and a low level of expression.
Nevertheless, nontoxic, tightly-regulated control of transgene expression has been achieved
with a tetracycline (Tet) gene control system [56]. Two types of Tet gene control system have
been devised. A Tet-Off system is one such system. It is composed of a Tet transactivator (a
hybrid protein termed tTA, which contains the Tet and DNA binding domains of the E. coli
Tet repressor fused to VP16, an HSV-1 transactivator) which binds to E. coli-derived Tet-
resistance operon regulatory elements embedded within a minimal CMV promoter (tetO/
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minCMV). Binding of tTA to this region recruits strong cellular transcription factors thus
inducing transcription of a transgene inserted downstream. When Tet is present, it binds to tTA
causing the dissociation of tTA from the tetO/minCMV complex thereby inhibiting transgene
expression. The second type of gene control system is the Tet-On system. Here tTA is modified
by four amino acids giving rise to the rtTA transactivator which, by itself is inactive, but in the
presence of the Tet analogue doxycycline (DOX), binds to the tetO/minCMV region and
induces high levels of transgene expression.
A number of Tet-regulatable viral systems have now been developed, including a Tet-off dual
adenoviral system for the ∃-gal reporter gene with the DNA sequence encoding the tTA
transactivator placed under the control of the hPRL promoter. With this system, specific
transgene expression in rodent lactotrophic cells was achieved both in vitro and in vivo.
Furthermore, this expression could be turned off by administration of DOX and then back on
when the antibiotic was removed [57]. A similar dual regulatable adenoviral vector system, in
this case expressing tyrosine hydroxylase (TH) under the control of the hCMV promoter, has
been also constructed. As TH is the rate-limiting enzyme for dopamine synthesis, the growth
of both lactotrophic cell lines (GH3 and MMQ) and estrogen-induced rat prolactinomas was
significantly inhibited when co-transduced with the two vector components of the regulatable
TH vector system. The expression of TH could be turned off by DOX, and back on by the
removal of the antibiotic [58].
We are currently constructing a bidirectional Tet-Off RAd expressing the gene for (GFP/
TK)fus and the gene for an analog of the antiinflammatory peptide, thymulin (Fig. 3).
Adenovirally-expressed thymulin displays an exceptional longetvity of expression (for a RAd)
in skeletal muscle and in the brain which is believed to be due to its antiinflammatory activity
[59,60; Fig. 4]. Therefore, the above bidirectional vector could allow effective TK suicide
pituitary tumor gene therapy without the inconvenience of inflammatory side effects.
POTENTIAL OF SUICIDE GENE THERAPY FOR THE TREATMENT OF HUMAN
PITUITARY TUMORS
The development of gene therapy approaches for pituitary tumors is still incipient. While some
of these approaches have already generated a core of results that emerge as a promising area
of research for the treatment of pituitary tumors, no clinical trials have yet been documented.
We are aware of only one gene therapy study using human pituitary cells. In this study, primary
cultures of human lactotroph adenoma cells were successfully transduced with an adenoviral
vector harboring the cDNA for human TH. The transduced cells not only expressed
immunocytochemically-detectable TH, but were also shown to release significant levels of L-
DOPA and dopamine which markedly reduced PRL release to the culture medium [61].
As already indicated, pituitary tumors seldom generate distant metastases. Although this
feature allows the surgeon to spare normal pituitary tissue without the risk of tumor cell
dissemination, neoplastic cells infiltrating the normal pituitary parenchyma may give rise to
tumor regrowths. As mentioned before, pituitary tumor surgery is usually complemented with
radiotherapy but, although this therapeutic combination is often effective to prevent tumor
regrowth, it usually causes hypopituitarism due to excessive destruction of the normal pituitary
parenchyma [62]. In this context, gene therapy appears to be a potentially superior alternative
to radiotherapy for the treatment of pituitary tumors. In effect, after tumor removal,
intrasurgical injection of an appropriate suicide vector into the spared pituitary parenchyma
could achieve complete elimination of remaining tumor cells without affecting healthy cells.
(Fig. 5). This therapeutic combination for the treatment of pituitary tumors has already been
proposed [63].
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Although gene therapy requires further investigation of its efficiency and safety before it can
be used for the treatment of pituitary diseases in humans, the versatility of this technique offers
unique possibilites for the development of new therapeutic tools for a wide range of
applications. These include tumor regression, supplementation of abnormal genes and
normalization of hormone secretion. When pituitary tumors do not respond to current
therapeutic strategies, pharmacological therapy is not well tolerated or the tumor becomes
aggressive or difficult to treat over time, gene therapy could be an attractive treatment modality.
Carefully designed and controlled clinical trials may assess the potential of gene therapy as a
useful treatment option for currently difficult-to-treat pituitary tumors such as Cushing’s or
non-secreting macroadenomas.
Combining current treatments, particularly surgery, with gene therapy could potentiate the
efficacy of the former and provide long-term remission and even cure for many types of
pituitary tumors. Although the field will need to advance further before gene therapy may
become a routine treatment for human pituitary tumors, it remains as a promising therapeutic
approach for the treatment of pituitary adenomas and tumors located in the sella turcica.
FIVE YEAR PROSPECT
Possibly, the most important issue that will have to be dealt with in the next five years, before
suicide gene therapy may be routinely used for the treatemnt of human pituitary tumors, is
adenovector-induced inflammation. As in other organs, adenoviral vectors have been shown
to cause inflammation in the pituitary gland, an adverse effect that could be prevented by using
bidirectional viral vectors expressing the gene for HSV-1 TK and the gene for an
antiinflamatory peptide like thymulin (see main text).
Alternatively, the use of less immunogenic viral vectors, like the adeno-associated viral
vectors, could be considered for the treatment of pituitary tumors. It should also be pointed out
that, although so far only the HSV1-TK-GCV suicide system has been used to implement
destructive experimental gene therapy of pituitary tumors, other available toxic systems might
offer advantages over the TK-GCV system. Thus, studies with recombinant Ad vectors
harboring cDNAs for three toxic genes, namely those encoding the HSV1-TK, the E. coli
cytosine deaminase and the deoxycytidine kinase, showed that cytosine deaminase had the
highest efficacy to reduce the growth of different human lung carcinoma cell lines [64].
Antisense and dominant negative gene therapies may constitute alternative strategies for the
treatment of pituitary tumors. Suppression of endogenous basic fibroblast growth factor
(bFGF) expression by means of an Ad vector carrying an antisense transgene for bFGF caused
inhibition of the proliferation of human glioma cells. The same effect was achieved by means
of an Ad vector carrying a transgene for a dominant negative FGF receptor [65].
Key issues
• Pituitary adenomas constitute the most frequent neuroendocrine pathology in humans.
• Current therapies for pituitary tumors have shown a significant degree of success but
in general, are neither devoid of unwanted side effects nor offer a permanent cure.
• The development of gene therapy approaches for the treatment of pituitary tumors
emerges as a novel interventive startegy.
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• Intrasurgical gene therapy using adenovectors expressing the suicide gene for
thymidine kinase appears as promising adjunt treatment to nonradical surgical
removal of pituitary tumors.
• Inflammation remains the most significant limitation of adenovirally-mediated
suicide gene therapy of pituitary tumors, an adverse effect that could be prevented by
using bidirectional viral vectors expressing the gene for TK and the gene for an
antiinflamatory peptide, like thymulin.
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Figure 1. Expression of transgenic (GFP/TK)fus in a rat pituitary adenoma
The main panel shows the green fluorescence of transduced cells around the entry point (arrow)
of the needle used to stereotaxically deliver RAd-(GFP/TK)fus into the tumor Obj. ×20. The
inset shows a low magnification view of the same pituitary adenoma where an entry point of
the needle can be seen (arrow). No structural damage is evident as a consequence of the
injection. Obj. ×4 (From Console et al., 2008, with permission)
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Figure 2. Suicide activity of a GFP/TK fusion protein
The suicide activity of an addenoviral vector, RAd-(GFP/TK)fus, harboring a DNA sequence
coding for the fusion protein (GFP/TK)fus, between eGFP and HSV-1 TK was tested in the
A549 human lung tumor cell line. Upper panels correspond to fluorescence images whereas
lower panels correspond to phase contrast images. The leftmost panel corresponds to control
cells (nuclei were labeled with DAPI and show blue fluorescence). Second panel from the left
corresponds to cells incubated for 4 days with 100 μM ganciclovir (GCV), and shows that the
viability of the cells was not affected by GCV alone. Third panel from the left corrsponds to
cells incubated for 4 days with RAd-(GFP/TK)fus. As expected green fluorescence is observed
in the cytoplasm of transduced cells. The rightmost panel corresponds to cells incubated during
4 days with the vector plus 100 μM GCV. A substantial reduction in the number of cells was
observed which confirms the suicide activity of the fusion protein. (Herenu et al.,
unpublished)
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Figure 3. Proposed bidirectional Tet-Off regulatable adenovector expressing a fluorescent form of
TK and the antiinflammatory peptide thymulin (FTS)
This adenovector, termed RAd-(TK/GFP-TRE-FTS), would combine the potent suicide
activity of HSV1 TK with the antiinflammatory action of FTS, thus avoiding unwanted damage
to healthy pituitary cells surrounding the tumor. Furthermore, the intrinsic green fluorescence
of the suicide protein would allow ready identification of transduced pituitary cells in
experimental tumors. The DOX-dependent regulatability of this system would enable the
experimenter to switch transgene expression off and back on by respectively adding and
removing the antibiotic DOX from the drinking water of the animals. Figure references:
metFTS, DNA sequence coding for a thymulin analog; PminCMV, minimal cytomegalovirus
promoter; TRE, tetracycline responsive element; ITR, inverted terminal repeat; Δ E1 and Δ
E3, deletions in the Ad5 genome; SV40, simian virus 40 polyadenylation signal; ψ, packaging
signal. (Herenu et al., unpublished)
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Figure 4. Differential length of expression for adenovirally delivered genes for thymulin, GFP and
β-gal in the rat brain
Adenoviral vectors harboring the genes fot βgal, GFP or thymulin (FTS), were injected into
de susbtantia nigra (SN) and medialbasal hypothalamus (MBH) of young rats and gene
expression assessed by immunofluorescence or bioassay at different times post vector
injection. Expression longevity of β-gal (left panel) and GFP (center panel) was much shorter
than that of FTS (right panel) in both brain regions. Bars over symbols represent SEM. Insets
show β-gal and GFP expression in the SN on post-injection day2. (Morel et al., unpublished)
Rodriguez et al. Page 16













Figure 5. Schematic representation of a possible application of suicide gene therapy to complement
surgical treatment of pituitary tumors
Initially the main tumor mass is removed, sparing the normal pituitary parenchyma.
Subsequently, the surgeon injects in the pituitary tissue that surrounded the tumoral mass a
suspension of an appropriate vector harboring the TK suicide transgene. A few days later the
patient is treated with ganciclovir for a convenient period of time in order to eliminate those
infiltrating tumor cells that escaped the surgical removal (from Goya et al, 2004, with
permission).
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Table 1




tumors Hormone expression Principal clinical manifestations
Prolactinomas 25–41 PRL Galactorrhea, hypogonadism
Somatotroph adenomas 10–20 GH (GH + PRL) Acromegalia
Corticotroph adenomas 5–15 ACTH Cushing’s syndrome (hypercortisolism)
Gonadotroph adenomas 10–15 FSH, LH, alpha subunit menstrual irregularities, hypopituitarism,
mechanical effects
Thyrotroph adenomas 0.5–2 TSH, alpha subunit hyperthyroidism
Null-cell adenomas 5–10 None mechanical effects, hypopituitarism
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